Payment overview · 2025
General Payments
$2,636.82
56 reported records · 16 companies
Healthcare provider profile · identity verified
Siddharth B Jani, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MOUNT CARMEL, IL · NPI 1497757595
Verified facts
What the public records show
CMS Open Payments records show Siddharth B Jani, M.D. received $2,636.82 in general payments during 2025 across 56 reported records.
Inspire Medical Systems, Inc. accounted for 61.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $1,607.07 | 61.0% | 14 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $201.93 | 7.7% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $154.61 | 5.9% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $128.39 | 4.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $97.78 | 3.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.13 | 2.9% | 4 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $72.60 | 2.8% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $71.38 | 2.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.21 | 2.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.22 | 1.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.41 | 1.3% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $28.77 | 1.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.44 | 1.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.52 | 0.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.05 | 0.5% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $10.31 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,335.77 | 5 |
| Food and Beverage | $1,151.05 | 50 |
| Consulting Fee | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $1,607.07 | 14 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $201.93 | 5 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $154.61 | 9 | 2025 |
Source payment records
|
|||||
| XYREM Normalized: xyrem |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $128.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.13 | 4 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $72.60 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $71.38 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.82 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.13 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $56.21 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.21 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.22 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.22 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.96 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.41 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $28.77 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.44 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $10.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 239 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
239 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 544 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 391 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 382 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 93 |
| Lisinopril | Lisinopril | 368 | 94 |
| Metformin Hcl | Metformin Hcl | 274 | 63 |
| Eliquis | Apixaban | 239 | 36 |
| Losartan Potassium | Losartan Potassium | 237 | 59 |
| Omeprazole | Omeprazole | 201 | 41 |
| Furosemide | Furosemide | 189 | 56 |
| Glimepiride | Glimepiride | 186 | 40 |
| Potassium Chloride | Potassium Chloride | 183 | 39 |
| Gabapentin | Gabapentin | 175 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 44 |
| Lorazepam | Lorazepam | 160 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 152 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 38 |
| Simvastatin | Simvastatin | 129 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 30 |
| Meloxicam | Meloxicam | 102 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 43 |
| Carvedilol | Carvedilol | 88 | 20 |
| Sertraline Hcl | Sertraline Hcl | 87 | 19 |
| Montelukast Sodium | Montelukast Sodium | 86 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 18 |
| Atenolol | Atenolol | 73 | 17 |
| Allopurinol | Allopurinol | 70 | 20 |
| Azithromycin | Azithromycin | 67 | 55 |
| Donepezil Hcl | Donepezil Hcl | 67 | 14 |
| Warfarin Sodium | Warfarin Sodium | 65 | 15 |
| Clonazepam | Clonazepam | 64 | suppressed |
| Januvia | Sitagliptin Phosphate | 63 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 13 |
| Alendronate Sodium | Alendronate Sodium | 55 | 15 |
| Alprazolam | Alprazolam | 55 | 11 |
| Valsartan | Valsartan | 55 | 12 |
| Prednisone | Prednisone | 53 | 29 |
| Memantine Hcl | Memantine Hcl | 52 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 12 |
| Spironolactone | Spironolactone | 48 | 14 |
| Ezetimibe | Ezetimibe | 47 | 13 |
| Tramadol Hcl | Tramadol Hcl | 47 | 19 |
| Cephalexin | Cephalexin | 44 | 38 |
| Finasteride | Finasteride | 43 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 20 |
| Famotidine | Famotidine | 36 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Dutasteride | Dutasteride | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 24 |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 21 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 12 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 21 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 22 |
| Amoxicillin | Amoxicillin | 23 | 22 |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 14 |
| Ozempic | Semaglutide | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Armodafinil | Armodafinil | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Dotti | Estradiol | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,636.82 · 56 records | Inspire Medical Systems, Inc. | BREZTRI, ELIQUIS, EVENITY, INSPIRE, Kerendia, LEQVIO, LUMRYZ, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REPATHA, Rybelsus, Sunosi, TRELEGY ELLIPTA, UBRELVY, WAKIX, WatchPATONE, XYREM, XYWAV, YUPELRI, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error